2025
Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham J, Neely M, Wojdyla D, Gulati M, Li P, Patel D, Palmer S, Todd J, Investigators I. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. CHEST Journal 2025 PMID: 40020995, DOI: 10.1016/j.chest.2025.02.018.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisLung transplantationLung function declinePulmonary fibrosisAssociated with 1.8-foldProgressive fibrosing interstitial lung diseaseMedian follow-up timeFibrosing interstitial lung diseaseFollow-up timeInterstitial lung diseaseCox proportional hazards modelsRisk of deathFunctional declineRisk of mortalityProportional hazards modelAntifibrotic treatmentThreshold of declineAssociated with lung function declineOutcomes RegistryLung diseaseEnrolling centersDLCOSmoking statusDiffusing capacityLung function
2024
129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease
Kern A, Voskrebenzev A, Klimeš F, Pink I, Schupp J, Seeliger B, Konietzke M, Peter D, Risse F, Welte T, Wacker F, Hohlfeld J, Shin H, Prasse A, Vogel-Claussen J. 129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease. 2024, oa5465. DOI: 10.1183/13993003.congress-2024.oa5465.Peer-Reviewed Original ResearchLung function and health-related quality of life among adult patients following pulmonary TB treatment.
Zawedde J, Abelman R, Musisi E, Nyabigambo A, Sanyu I, Kaswabuli S, Byanyima P, Lewis E, Sessolo A, Lalitha R, Kiwanuka N, Crothers K, Worodria W, Davis J, Huang L. Lung function and health-related quality of life among adult patients following pulmonary TB treatment. The International Journal Of Tuberculosis And Lung Disease 2024, 28: 419-426. PMID: 39187999, DOI: 10.5588/ijtld.24.0029.Peer-Reviewed Original ResearchConceptsSt. George's Respiratory QuestionnaireQuality of lifeAbnormal lung functionSpirometric restrictionHealth-related quality of lifeLung functionPost-TB lung diseaseHealth-related qualityFemale sexRisk factorsFunctional abnormalitiesGeorge's Respiratory QuestionnairePTB treatmentPulmonary TB treatmentAssociated with increased morbidityChronic lung complicationsPrevalence ratiosResource-limited settingsChest X-rayLung function abnormalitiesRespiratory QuestionnaireSGRQ scoreAssociated with lung function abnormalitiesSmoking statusBilateral consolidationAdjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.
Wallis R, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evidence 2024, 3: evidoa2300332. PMID: 39189858, DOI: 10.1056/evidoa2300332.Peer-Reviewed Original ResearchConceptsWhole blood glutathione levelsLung functionN-acetylcysteinePulmonary tuberculosisCulture conversionSecondary outcomesGlutathione levelsEffect of N-acetylcysteineTuberculosis treatment outcomesOutcome of lung functionOral N-acetylcysteineRecovery of lung functionAdjunctive N-acetylcysteineAssociated with improved recoveryN-acetylcysteine treatmentPermanent lung injuryFar-advanced tuberculosisSputum cultureStandard therapyNAC administrationAdverse eventsLung injuryGlobal health concernCohort studyClinical evaluationPersonal exposure to airborne organic pollutants and lung function changes among healthy older adults
Guo X, Ren H, Sun P, Ding E, Fang J, Fang K, Ma X, Li C, Li C, Xu Y, Cao K, Lin E, Guo P, Pollitt K, Tong S, Tang S, Shi X. Personal exposure to airborne organic pollutants and lung function changes among healthy older adults. Environmental Research 2024, 258: 119411. PMID: 38876423, DOI: 10.1016/j.envres.2024.119411.Peer-Reviewed Original ResearchUnderstanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment
Benn B, Lippitt W, Cortopassi I, Balasubramani G, Barbosa E, Drake W, Herzog E, Gibson K, Chen E, Koth L, Fuhrman C, Lynch D, Kaminski N, Wisniewski S, Carlson N, Maier L. Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment. CHEST Journal 2024, 166: 1093-1107. PMID: 38830401, PMCID: PMC11560486, DOI: 10.1016/j.chest.2024.04.031.Peer-Reviewed Original ResearchScadding stageCT featuresLung functionChest radiologistsCT scanAlpha-1 anti-trypsin deficiencyChest computed tomographyChest CT scanChest X-rayIncreasing clinical useCompare demographic featuresAssociated with FEV1Visual scoring systemSarcoidosis stagePulmonary sarcoidosisChest CTCT findingsAssociated with lung functionCT assessmentComputed tomographySarcoidosisClinical useRadiological measurementsCT measurementsScoring systemLongitudinal Data Analysis
Diggle P, Taylor-Robinson D. Longitudinal Data Analysis. 2024, 1-34. DOI: 10.1007/978-1-4614-6625-3_75-1.Peer-Reviewed Original ResearchTime-to-event outcomesBinary responsesTreatment of missing valuesClinical trials of drug therapyJoint modelTrials of drug therapyCystic fibrosis patientsLongitudinal studyLinear modelCross-sectional studySchizophrenia patientsFibrosis patientsLong-term progressionDrug therapyClinical trialsLung functionObservational studyNon-independencePatientsOutcome variablesStatistical methodsDevelopmental changes in lung function of mice are independent of sex as a biological variable
Bärnthaler T, Ramachandra A, Ebanks S, Guerrera N, Sharma L, Dela Cruz C, Humphrey J, Manning E. Developmental changes in lung function of mice are independent of sex as a biological variable. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2024, 326: l627-l637. PMID: 38375577, PMCID: PMC11380952, DOI: 10.1152/ajplung.00120.2023.Peer-Reviewed Original ResearchPulmonary function testsWeeks of ageStatic complianceMale miceInspiratory capacityLung functionBody weight-basedHuman lung pathologiesLung function of miceFemale C57BL/6J miceLung function parametersSex-dependent changesFunction of miceMeasures of lung functionIndependent of sexPreclinical modelsFemale miceC57BL/6J miceLung pathologyFunction testsMiceWeight-basedLungLung disease researchWeeks
2023
So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer
Detterbeck F, Ely S, Udelsman B, Blasberg J, Boffa D, Dhanasopon A, Mase V, Woodard G. So Now We Know—Reflections on the Extent of Resection for Stage I Lung Cancer. Clinical Lung Cancer 2023, 25: e113-e123. PMID: 38310034, DOI: 10.1016/j.cllc.2023.12.007.Peer-Reviewed Original ResearchStage I lung cancerI lung cancerSublobar resectionRecurrence-free survivalHealthy patientsLung cancerRecent trialsInadequate resection marginsLarge recent trialsAdditional randomized trialsHigh-level evidenceOverall survival differenceExtent of resectionLong-term outcomesLong-term resultsHigh locoregional recurrenceAspects of patientsLesser resectionsLocoregional recurrencePerioperative morbidityIntraoperative detailsLung functionResection extentResection marginsPostoperative changesDexmedetomidine improves pulmonary outcomes in thoracic surgery under one-lung ventilation: A meta-analysis
Zorrilla-Vaca A, Grant M, Law M, Messinger C, Pelosi P, Varelmann D. Dexmedetomidine improves pulmonary outcomes in thoracic surgery under one-lung ventilation: A meta-analysis. Journal Of Clinical Anesthesia 2023, 93: 111345. PMID: 37988813, PMCID: PMC11034816, DOI: 10.1016/j.jclinane.2023.111345.Peer-Reviewed Original ResearchAcute respiratory distress syndromePostoperative pulmonary complicationsOne-lung ventilationThoracic surgeryDexmedetomidine groupPlacebo groupPostoperative atelectasisRandomized trialsOdds ratioIncidence of PPCsImpact of dexmedetomidineIntraoperative respiratory mechanicsPostoperative lung functionRespiratory distress syndromeML/cmHRandom-effects modelPostoperative pneumoniaPulmonary complicationsPulmonary outcomesIntrapulmonary shuntPostoperative FEV1Secondary outcomesDistress syndromeLung functionPrimary outcomeRespect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingSex modifies the risk of HIV-associated obstructive lung disease in Ugandans postpneumonia
Abelman R, Fitzpatrick J, Zawedde J, Sanyu I, Byanyima P, Kaswabuli S, Musisi E, Hsieh J, Gardner K, Zhang M, Byanova K, Sessolo A, Hunt P, Lalitha R, Davis J, Crothers K, Worodria W, Huang L. Sex modifies the risk of HIV-associated obstructive lung disease in Ugandans postpneumonia. AIDS 2023, 37: 1683-1692. PMID: 37352494, PMCID: PMC10527596, DOI: 10.1097/qad.0000000000003626.Peer-Reviewed Original ResearchConceptsObstructive lung diseaseLung diseaseLung functionAbnormal lung functionMultivariable regression modelsWarrants further studyCommon comorbiditiesExpiratory volumeSpirometric abnormalitiesSmoking statusSpirometric testingTB statusVital capacitySex modifiesStratified analysisHIVWomenDiseaseComorbiditiesMenSexFurther studiesGreater degreeRiskTuberculosisEffects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold A, Kuwana M, Merkel P, Stock C, Sambevski S, Denton C, Bergna M, Casado G, Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R, Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Devi H, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S, Cheah C, Kan S, Mohamed R, Selman M, de Vries-Bouwstra J, van den Toorn L, Vonk M, Voskuyl A, Hoffmann-Vold A, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M, Sancho J, Delgado P, Barranco I, Martínez J, del Castillo A, Ovalles J, López-Longo F, Gallego A, Dapena M, Ivorra J, Ekwall A, Maurer B, Mihai C, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C, Herrick A, Madhok R, Maher T, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M, D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L, Luckhardt T, Mayes M, Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology 2023, 63: 639-647. PMID: 37294870, PMCID: PMC10907814, DOI: 10.1093/rheumatology/kead280.Peer-Reviewed Original ResearchLimited cutaneous systemic sclerosisInterstitial lung diseaseCutaneous systemic sclerosisSENSCIS trialEffect of nintedanibWeek 52Nintedanib groupPlacebo groupSystemic sclerosisLung diseaseProgressive fibrosing interstitial lung diseasesOpen-label nintedanibSSc-ILDLung functionPulmonary fibrosisNintedanibPatientsRate of declineFVCTrialsPlaceboSclerosisDiseaseGroupFibrosisEffect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalizationDupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status
Rabe K, Pavord I, Busse W, Chupp G, Izuhara K, Altincatal A, Gall R, Pandit‐Abid N, Deniz Y, Rowe P, Jacob‐Nara J, Radwan A. Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy 2023, 78: 2148-2156. PMID: 37073882, DOI: 10.1111/all.15747.Peer-Reviewed Original ResearchConceptsParent study baselineType 2 inflammationPre-bronchodilator FEVAsthma exacerbation rateType 2 asthmaAllergic asthmaExacerbation rateSevere asthma exacerbation ratesSevere type 2 asthmaAsthma Control Questionnaire scoreACQ-5 scoresReduced exacerbation ratesLong-term outcomesLong-term treatmentAllergic statusDupilumab efficacyGINA guidelinesQUEST studyWeek 96Asthma controlUncontrolled asthmaWeek 48Allergic phenotypeLung functionQuestionnaire scoresZiritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
Maher T, Ford P, Brown K, Costabel U, Cottin V, Danoff S, Groenveld I, Helmer E, Jenkins R, Milner J, Molenberghs G, Penninckx B, Randall M, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins T, Wuyts W, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek M, Chambers D, Chia M, Corte T, Glaspole I, Goh N, Holmes M, Malouf M, Thien F, Veitch E, Bondue B, Dahlqvist C, Froidure A, Slabbynck H, Wuyts W, Cartagena Salinas C, Feijoó Seoane R, Martínez V, Maturana R, Pavie Gallegos J, Rosenblut A, Silva R, Undurraga Pereira A, Doubkova M, Pauk N, Plackova M, Sterclova M, Bendstrup E, Shaker S, Titlestad I, Budweiser S, Grohé C, Koschel D, Kreuter M, Prasse A, Weber M, Wirtz H, Antoniou K, Daniil Z, Gaga M, Papakosta D, Izumi S, Okamoto M, Guerreros Benavides A, Iberico Barrera C, Peña Villalobos A, Campo Ezquibela A, Cifrian Martinez J, Fernandez Fabrellas E, Leiro V, Molina-Molina M, Nieto Barbero A, Sellares Torres J, Valenzuela C, Cheng S, Kuo P, Lee K, Sheu C, Gunen H, Mogulkoc Bishop N, Nayci S, Adamali H, Bianchi S, Chaudhuri N, Gibbons M, Hart S, Molyneaux P, Parfrey H, Saini G, Spencer L, Wiscombe S, Antin-Ozerkis D, Bascom R, Belperio J, Britt E, Fitzgerald J, Gomez Manjarres D, Gotfried M, Gupta N, Hotchkin D, Kaye M, Kreider M, Kureishy S, Lacamera P, Lancaster L, Lasky J, Lorch D, Mannem H, Morrow L, Moua T, Nambiar A, Raghu G, Raj R, Ramaswamy M, Reddy R, Russell T, Scholand M, Shea B, Suliman S, Swigris J, Thavarajah K, Tolle L, Tomic R, Warshoff N, Wesselius L, Yung G, Bergna M, De Salvo M, Fernandez Acquier M, Rodriguez A, Saez Scherbovsky P, Assayag D, Dhar A, Khalil N, Morisset J, Provencher S, Ryerson C, Shapera S, Bourdin A, Crestani B, Lebargy F, Reynaud-Gaubert M, Bonella F, Claussen M, Hammerl P, Karagiannidis C, Keller C, Randerath W, Stubbe B, Csánky E, Medgyasszay B, Muller V, Adir Y, Bar-Shai A, Berkman N, Fink G, Kramer M, Shitrit D, Bargagli E, Gasparini S, Harari S, Ravaglia C, Richeldi L, Vancheri C, Ebina M, Fujita M, Ichikado K, Inoue Y, Ishikawa N, Kato M, Kawamura T, Kondoh Y, Nishioka Y, Ogura T, Owan I, Saito T, Sakamoto N, Sakamoto K, Shirai M, Suda T, Tomii K, Chung M, Jeong S, Park C, Park J, Song J, Uh S, Chavarria Martinez U, Montano Gonzalez E, Ramirez A, Selman Lama M, Bresser P, Kramer H, Mostard R, Nossent E, Veltkamp M, Wijsenbeek M, Beckert L, Chang C, Veale A, Wilsher M, Bednarek M, Gasior G, Jasieniak-Pinis G, Jassem E, Mroz R, Piotrowski W, Abdullah I, Ambaram A, Irusen E, Van der Linden M, van Zyl-Smit R, Williams P, Allen J, Averill F, Belloli E, Brown A, Case A, Chaudhary S, Criner G, DeBoer K, Dilling D, Dorf J, Enelow R, Ettinger N, Feldman J, Gibson K, Golden J, Hamblin M, Hunninghake G, Karunakara R, Kim H, Luckhardt T, Menon P, Morrison L, Oldham J, Patel N, Schmidt S, Strek M, Summer R, Sussman R, Tita J, Veeraraghavan S, Whelan T, Zibrak J. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis. JAMA 2023, 329: 1567-1578. PMID: 37159034, PMCID: PMC10170340, DOI: 10.1001/jama.2023.5355.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedClinical Trials, Phase III as TopicFemaleHumansIdiopathic Pulmonary FibrosisLungMaleMiddle AgedMulticenter Studies as TopicPhosphodiesterase InhibitorsQuality of LifeRandomized Controlled Trials as TopicRespiratory Physiological PhenomenaRespiratory System AgentsTreatment OutcomeConceptsIdiopathic pulmonary fibrosisKey secondary outcomesFVC declineSecondary outcomesPulmonary fibrosisCare treatmentSt George's Respiratory Questionnaire (SGRQ) total scoreRespiratory-related hospitalizationsSafety Monitoring CommitteeQuestionnaire total scoreNovel autotaxin inhibitorAnnual rateCause mortalityWeek 52Lung functionPrimary outcomeClinical outcomesVital capacityStudy terminationClinical trialsDisease progressionPlaceboMAIN OUTCOMEPatientsAutotaxin inhibitorsRemission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goalsAdaptation of Nontypeable Haemophilus influenzae in Human Airways in COPD: Genome Rearrangements and Modulation of Expression of HMW1 and HMW2
Murphy T, Kirkham C, D’Mello A, Sethi S, Pettigrew M, Tettelin H. Adaptation of Nontypeable Haemophilus influenzae in Human Airways in COPD: Genome Rearrangements and Modulation of Expression of HMW1 and HMW2. MBio 2023, 14: e00140-23. PMID: 36927061, PMCID: PMC10127715, DOI: 10.1128/mbio.00140-23.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseNontypeable Haemophilus influenzaeObstructive pulmonary diseaseRespiratory epithelial cellsHuman airwaysHaemophilus influenzaeAirway inflammationLung functionMechanisms of persistencePulmonary diseaseEpithelial cellsNovel interventionsChronic lower airway infectionsProgressive lossAirways of adultsLower airway infectionHuman respiratory epithelial cellsCommon debilitating disorderStrains of NTHiNTHi infectionAirway infectionLower airwaysCommon causeSequential isolatesSerial isolatesThree Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients
Makinde H, Dunn JLM, Gadhvi G, Carns M, Aren K, Chung AH, Muhammad LN, Song J, Cuda CM, Dominguez S, Pandolfino JE, D'Amico J, Budinger GS, Assassi S, Frech TM, Khanna D, Shaeffer A, Perlman H, Hinchcliff M, Winter DR. Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma Patients. Arthritis & Rheumatology 2023, 75: 595-608. PMID: 36281773, PMCID: PMC10165944, DOI: 10.1002/art.42380.Peer-Reviewed Original ResearchConceptsDiffuse cutaneous systemic sclerosisNonclassical monocytesClassical monocytesSSc patientsTranscriptional signatureSystemic sclerosisSkin diseasesCharacteristic transcriptional signaturesRNA-seq dataSSc skin diseaseWorse lung functionCutaneous systemic sclerosisEarly systemic sclerosisActivity outcome measuresDistinct transcriptional profilesTranscriptional profilingRNA sequencingTranscriptional profilesProspective registryDisease activityLung functionComplex clinical phenotypeGene expressionPeripheral bloodMinority cell populationLearnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
Higuero Sevilla J, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 118. PMID: 37422652, PMCID: PMC10329300, DOI: 10.1186/s13075-023-03090-y.Peer-Reviewed Original ResearchConceptsConnective tissue disease-associated interstitial lung diseaseInterstitial lung diseaseTreatment of patientsMycophenolate mofetilSSc-ILDLung diseaseClinical trialsScleroderma Lung Study IIPatient-reported outcome instrumentsIdiopathic inflammatory myositisClinical trial resultsInflammatory myositisIntravenous cyclophosphamideOral cyclophosphamideSubcutaneous tocilizumabGood tolerabilityLung functionSystemic sclerosisTreatment armamentariumRheumatoid arthritisPatient outcomesSimilar efficacyOutcome instrumentsPatientsUS Food
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply